| Felipe Sebastian De Puigdorfila, | |
|
58 Calle Yaguez, Aguas Buenas, PR 00703-9632 | |
| (787) 233-6272 | |
| Not Available |
| Full Name | Felipe Sebastian De Puigdorfila |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 58 Calle Yaguez, Aguas Buenas, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053913772 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 4469 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Felipe Sebastian De Puigdorfila, 58 Calle Yaguez, Aguas Buenas, PR 00703-9632 Ph: (787) 233-6272 | Felipe Sebastian De Puigdorfila, 58 Calle Yaguez, Aguas Buenas, PR 00703-9632 Ph: (787) 233-6272 |
News Archive
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.
Between 8.5 percent and 14 percent of soldiers returning from Iraq report serious functional impairment due to either posttraumatic stress disorder or depression, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Physio-Control, a global leader in emergency medical solutions and wholly-owned subsidiary of Medtronic, and BeneChill, a pioneer in portable therapeutic cooling systems, today announced a strategic partnership to launch the RhinoChill IntraNasal Cooling System in Europe.
Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker which makes it possible to identify women with uterine cancer who have a high risk of recurrence.
› Verified 7 days ago
Mr. Carlos Enrique Cartagena Diaz, Counselor Medicare: Not Enrolled in Medicare Practice Location: Hc 3 Box 15163, Aguas Buenas, PR 00703 Phone: 787-453-8577 |